Branded Legacy, Inc. (OTC: BLEG) has initiated preparation of its FDA Pre-Abbreviated New Drug Application briefing package for a proprietary intranasal naloxone spray through its subsidiary BioLegacy Evaluative Group. This regulatory milestone follows the company's provisional patent filing for an air-driven delivery platform designed to address the ongoing opioid overdose crisis with a cost-effective, scalable solution.
The submission package includes comprehensive documentation required for FDA review, featuring a Target Product Profile for both 2 mg and 4 mg naloxone HCl nasal sprays. The company has developed detailed Chemistry, Manufacturing and Controls specifications and plans to conduct a 60-subject bioequivalence study comparing their product against the established Narcan(R) formulation. Human factors testing is also incorporated to ensure the product remains accessible for non-medical users, a critical consideration for widespread deployment in community settings.
Kristian Thorlund, Executive Chair of Branded Legacy, emphasized the strategic importance of their development approach, stating that their intranasal platform aims to replicate Narcan performance while significantly reducing cost and improving global accessibility. This dual focus on efficacy and affordability represents a potential breakthrough in making life-saving overdose reversal medication more widely available to communities disproportionately affected by the opioid epidemic.
The company's progress comes at a critical time when opioid-related deaths continue to pose significant public health challenges across multiple regions. The development of alternative naloxone delivery systems could potentially expand access to emergency treatment options in both medical and community settings. For more information about the company's initiatives, visit https://BrandedLegacy.com.
Branded Legacy operates through strategic collaborations with leading academic institutions including McMaster University and Stanford University, leveraging these partnerships to drive transformative research in addiction treatment and harm reduction. The company maintains a state-of-the-art GMP manufacturing facility in Vancouver, providing advanced production capabilities necessary for developing cutting-edge pharmaceutical products.
The advancement of this intranasal naloxone formulation through the FDA regulatory pathway represents an important step in expanding the toolkit available for addressing opioid overdose emergencies. As communities continue to grapple with the devastating effects of the opioid crisis, the development of more accessible and affordable reversal medications could have significant implications for public health outcomes and emergency response capabilities worldwide.
